Kishvog-MV1 Tablet SR is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride 1 mg, Metformin 500 mg, and Voglibose 0.2 mg, each contributing distinct mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, thereby reducing postprandial hyperglycemia. The sustained-release (SR) formulation ensures a gradual and prolonged release of active ingredients, promoting better patient compliance and stable plasma drug concentrations. Kishvog-MV1 is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. It is essential to monitor blood glucose levels regularly and adjust dosage accordingly to minimize the risk of hypoglycemia and gastrointestinal side effects. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or hypersensitivity to any component. This combination therapy offers a comprehensive approach to managing hyperglycemia by targeting multiple pathophysiological defects in type 2 diabetes.